379 related articles for article (PubMed ID: 14553866)
1. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
2. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
3. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
5. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
Molavi B; Rassouli N; Bagwe S; Rasouli N
Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815
[TBL] [Abstract][Full Text] [Related]
6. Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Stafford JM; Elasy T
Vasc Health Risk Manag; 2007; 3(4):503-10. PubMed ID: 17969380
[TBL] [Abstract][Full Text] [Related]
7. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Zinn A; Felson S; Fisher E; Schwartzbard A
Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Seufert J; Lübben G; Dietrich K; Bates PC
Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
[TBL] [Abstract][Full Text] [Related]
9. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Satoh J
Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
[TBL] [Abstract][Full Text] [Related]
10. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
11. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
14. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.
Bailey CJ
Diabetes Obes Metab; 2005 Nov; 7(6):675-91. PubMed ID: 16219011
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
17. Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.
Smiley D; Umpierrez G
Expert Opin Pharmacother; 2007 Jun; 8(9):1353-64. PubMed ID: 17563269
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Significance of PPAR Gamma Agonism.
Campbell IW
Curr Mol Med; 2005 May; 5(3):349-63. PubMed ID: 15892654
[TBL] [Abstract][Full Text] [Related]
19. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
20. PPARS, insulin resistance and type 2 diabetes.
Kaplan F; Al-Majali K; Betteridge DJ
J Cardiovasc Risk; 2001 Aug; 8(4):211-7. PubMed ID: 11550999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
